Corner Therapeutics announces $54 million Series A funding

19 April 2024

US immune therapies and vaccines developer Corner Therapeutics has raised $54 million to create vaccines that confer lifelong protection from cancer and infectious diseases.

The funding, led by Ziff Capital Partners and including Cockrell Interests, Tanis Ventures, and Sandia Holdings, will boost Corner’s mission to enable the immune system to engineer long-living, disease-fighting T cells.

Corner is bringing its antigen agnostic technology to the development of vaccines against cancer and infectious disease. Grant funding from the Bill & Melinda Gates Foundation is helping Corner to apply its approach to infectious diseases such as HIV, influenza and COVID-19, the company noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK